Virios Therapeutics Inc
Change company Symbol lookup
Select an option...
VIRI Virios Therapeutics Inc
EPRT Essential Properties Realty Trust Inc
CRIS Curis Inc
PIXY ShiftPixy Inc
RVLP RVL Pharmaceuticals PLC
NAUT Nautilus Biotechnology Inc
BOF BranchOut Food Inc
SPRC Scisparc Ltd
NRSN Neurosense Therapeutics Ltd
ACNT Ascent Industries Co
Go

Health Care : Biotechnology | Small Cap Value

Virios Therapeutics, Inc. is a development-stage biotechnology company focused on advancing antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (FM). The Company’s lead development candidate is IMC-1, which is a fixed dose combination of famciclovir, and celecoxib designed to synergistically suppress herpes virus replication. IMC-1 combines these two specific mechanisms of action purposely designed to inhibit herpes virus activation and replication. The Company’s pipeline product includes IMC-2 (valacyclovir and celecoxib), which is in the Phase 1 development stage. IMC-2 (valacyclovir and celecoxib) is developed for treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with Long-COVID or Post-Acute Sequelae of COVID-19 (PASC).

Postmarket

Last Trade: Delayed
$0.8902

Change Since Close Change Since Close Postmarket extended hours change is based on the last price at the end of the regular hours period. Premarket extended hours change is based on the day's regular session close.: -0.033 (-3.57%)

Bid: --

Ask: --

B/A Size: --

Market Hours

Closing Price: $0.9232

Day's Change: -0.0368 (-3.84%)

Bid close: --

Ask close: --

B/A Size: --

Day's High: 0.9399

Day's Low: 0.8851

Volume (Below Average) Volume: 120,589 10-day average volume: 149,811: 120,589

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.

Postmarket

Change Since Close

Market Hours